“B2B” aims to generate a first-of-a-kind 3D model of spontaneous breast cancer metastasis to the bone to dissect the complexity of the metastatic process and empower high-throughput drug screening in a physiological context. A challenging, as well as timely topic, where we will work with a fantastic team, aiming to transcend the limitations of current in-vitro technologies and provide a breakthrough approach to investigate metastasis longitudinally and at the single cell level.
It looks like BET meets FET at last!
23 February 2018